Femasys announces $3.9 million registered direct offering priced at-the-market under nasdaq rules

Atlanta, april 19, 2023 (globe newswire) -- femasys inc. (nasdaq: femy), a biomedical company aiming to meet women's needs by developing a suite of products and product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 3,196,722 of its shares of common stock (or common stock equivalents) at a purchase price of $1.22 per share (or common stock equivalent) in a registered direct offering priced at-the-market under nasdaq rules. in a concurrent private placement, femasys has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 3,196,722 shares of common stock. the offering is expected to close on or about april 20, 2023, subject to the satisfaction of customary closing conditions.
FEMY Ratings Summary
FEMY Quant Ranking